INC Research, Inc. Leads Conversation On Evolving Outsourcing Models at SCOPE
2/3/2014 10:27:05 AM
Raleigh, N.C., Feb. 3, 2014 – INC Research, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced CEO Jamie Macdonald will participate in a panel discussion on evolving outsourcing models at Cambridge Healthtech Institute’s Fifth Annual Summit for Clinical Operations Pharmaceutical Executives (SCOPE), Feb. 4-6, 2014, in Miami, Fla. In addition to Macdonald’s participation in a panel discussion, Company experts will be on-hand at Booth #10 to discuss how its unique risk-based monitoring approach keeps customers, investigative sites and patients more connected throughout the entire clinical development process.
“With cost and timeline pressures mounting, it’s time to take a hard look at our existing relationship models to determine how we can more effectively allocate resources to improve the drug development process for all involved,” said INC Research CEO Jamie Macdonald. “SCOPE provides an opportunity for key industry stakeholders to discuss how to break down the silos and let go of some of the more traditional relationship models. We look forward to sharing how INC Research is accelerating delivery of products to patients by connecting with sites and patients more effectively through a combination of cutting-edge technologies and therapeutic and operational expertise.”
Macdonald’s panel discussion, “New Frontiers in Collaboration among Key Industry Stakeholders” takes place on Wednesday, Feb. 5 at 4:55 p.m. The panel will offer attendees an opportunity to hear from key industry stakeholders as they re-examine traditional pharma/CRO/site relationship models.
At SCOPE, INC Research also will be comparing different approaches to risk-based monitoring, including its own Strategic Data Monitoring solution, which takes a more holistic approach through the development of fit-for-purpose operational strategies. Visitors can stop by the INC Research Booth #10 to pick up a copy of Risk-Based Monitoring: An overview of best practice recommendations for a summary of the latest approaches toward monitoring to improve efficiency, data quality and patient safety.
As a therapeutically-focused CRO, INC Research works closely with investigators, patients, technology experts, and regulatory authorities all over the globe. Providing a full range of Phase I to IV clinical development services on a worldwide scale, INC Research helps biopharmaceutical companies efficiently bring new drugs to market through a proven methodology that ensures consistent quality, reduced trial variability and complete transparency for every phase of a development program. Using advanced data monitoring and management systems, INC Research is able to provide a real-time status on all projects and test sites and help identify issues before they occur, giving sponsors a high level of visibility and predictability throughout their clinical trial programs.
For more information or to schedule a meeting at SCOPE, visit the INC Research site or stop by Booth #10 at the conference.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
Help employers find you! Check out all the jobs and post your resume.
comments powered by